Integer Holdings (ITGR)
(Delayed Data from NYSE)
$132.43 USD
+3.19 (2.47%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $132.54 +0.11 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$132.43 USD
+3.19 (2.47%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $132.54 +0.11 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
Zacks News
Abaxis' (ABAX) Preliminary Results for Q3 Cheer Investors
by Zacks Equity Research
Abaxis (ABAX) expects substantial tax savings from the recent U.S. tax reform.
Hill-Rom (HRC) Estimates Strong Revenue Figures for Q1
by Zacks Equity Research
Hill-Rom (HRC) expects substantial tax savings from the recent U.S. tax reform.
NuVasive Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
NuVasive (NUVA) continues to witness sequential growth in international revenues and expects substantial tax savings from the recent U.S. tax reform.
DexCom Estimates Strong Revenue Figures for Q4 and 2017
by Zacks Equity Research
Dexcom (DXCM) to gain from strong sensor volumes, international revenues and expanding worldwide patient base in 2018.
AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2
by Zacks Equity Research
Dwindling revenues in two major segments hurt AngioDynamics' (ANGO) second-quarter results.
McKesson Buys RxCrossroads from CVS Health for $735 Million
by Zacks Equity Research
McKesson (MCK) has been actively pursuing deals, divestitures and acquisitions to drive growth. The latest buyout will boost Specialty Health business.
Walgreens Boots (WBA) Tops Q1 Earnings, Margins Decline
by Zacks Equity Research
Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q1 on continued prescription growth and strength in the Retail Pharmacy USA division.
Neogen (NEOG) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Neogen (NEOG) rides high on balanced growth across all business segments in Q2.
Entellus (ENTL) Nears 52-Week High: What's Driving It?
by Zacks Equity Research
Entellus Medical Inc. (ENTL) gains from latest technology and promising revenue trends.
LabCorp Grapples With Reimbursement Cuts, Stiff Competition
by Zacks Equity Research
LabCorp (LH) faces intense competition from hospital-affiliated labs, primarily on the basis of quality of service.
Stryker's Global Foothold Strong Amid Product Recall Issue
by Zacks Equity Research
Stryker (SYK) enjoys strong foothold in the European and Australian markets. On the flip side, the company witnesses lower demand for health care products.
Anika Therapeutics Receives FDA Nod for Bone Repair Therapy
by Zacks Equity Research
Anika Therapeutics' (ANIK) FDA approved HA-based injectable bone repair therapy provides a commercial edge to regenerative portfolio.
5 Reasons Why You Should Buy Abiomed (ABMD) Stock Right Now
by Zacks Equity Research
Abiomed (ABMD) gains from solid product portfolio. Also, impressive performance on the bourses instills investor's optimism on the stock.
Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?
by Zacks Equity Research
Cogentix Medical (CGNT) stock continues to hover around the 52-week high mark reached on Dec 27, courtesy of its new strategies.
Robust Pipeline Aids Edwards Lifesciences, Rising Costs Ail
by Zacks Equity Research
Edwards Lifesciences' (EW) pipeline building to fortify foothold across all operating businesses bodes well. Also, the TAVR adoption rate across Japan and the European countries is impressive.
Align Rides on Balanced Segmental Growth Amid Stiff Contest
by Zacks Equity Research
Align (ALGN) gains from balanced sales growth across all its channels of late, primarily on high InvisAlign Technology case volumes.
New Strong Sell Stocks for November 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Integer (ITGR) Q2 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Integer's (ITGR) strong performance in the Cardio and Vascular business was a key highlight in second quarter 2017.
Integer (ITGR) Up 9.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Integer (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integer (ITGR) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Integer Holdings Corporation (ITGR) reported adjusted earnings of 41 cents per share in the first quarter of 2017, a penny down on a year-over-year basis.
Medical Product Q1 Earnings on May 8: ITGR, OPK & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 8.
Integer (ITGR) Amends Term B Loan to Lower Interest Rate
by Zacks Equity Research
Integer Holdings Corporation (ITGR) announced that it has completed an amendment to its senior secured credit facilities to lower the interest rate on its Term B Loan Facility.
Integer (ITGR) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Integer Holdings (ITGR) reported adjusted earnings of 87 cents per share in the fourth quarter of 2016, lower than the year-ago quarter figure of 92 cents.
Integer (ITGR) to Co-Develop CCM Therapy with Impulse Dynamics
by Zacks Equity Research
Integer Holdings Corporation (ITGR) announced that it has signed a development agreement with Impulse Dynamics.